Page 14 - Flipbook

Conclusions

• Galsky:

• TURBT + gemcitabine, cisplatin, plus nivolumab achieves stringently defined cCR

in a large subset of patients with MIBC

• 1-year bladder intact survival is possible though the durability of responses

• The role of genomic biomarkers in management algorithms, requires longer

follow-up

• Balar:

• Pembro added to hypofractionated RT and twice weekly gem was well-tolerated

with promising efficacy in this early analysis

• Pembro-related toxicity was consistent with prior monotherapy trials

• del Muro

• durvalumab + tremelimumab with concurrent RT is feasible and safe, showing

high efficacy in terms of response and eliciting bladder preservation in a large
number of pts.

Radiation Oncology